Biopharma firm DBV Technologies SA's DBVT submission of BLA (biologics license application to the US FDA) for its VIASKIN peanut patch in children remains on track for the first half of this year, ...

DBV Technologies (DBVT) trades at a ~$1B market cap, but Viaskin faces a shrinking peanut allergy market and formidable competition, warranting caution. Viaskin’s addressable market is materially ...

DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced plans to initiate a new, pivotal Phase 3 clinical ...

DBV to pursue an Accelerated Approval pathway for toddlers ages 1 - 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris ...

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT - CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American ...

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés ...

Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration DocumentDBV ...

If you are wondering whether DBV Technologies is still attractively priced after its recent run, you are not alone. This article unpacks what the current share price could imply about value. The stock ...

DBV Technologies has posted phase 3 data suggesting safety and compliance are unlikely to scuttle its hopes of winning approval of peanut allergy treatment Viaskin Peanut. Shares in DBV rose on the ...